達剛控股(300103.SZ)完成向子公司達剛科技實繳出資5000萬元
格隆匯12月16日丨達剛控股(300103.SZ)公佈,公司第四屆董事會第二十二次(臨時)會議審議通過了《關於使用部分超募資金投資設立全資子公司的議案》,同意公司使用超募資金5000萬元人民幣在陝西省渭南市高新技術產業開發區設立全資子公司。
2019年10月,上述全資子公司完成了工商登記手續,名稱為陝西達剛裝備科技有限公司(“達剛科技”)。
截至公告日,公司已完成了對達剛科技共計5000萬元人民幣的實繳出資。
此次向全資子公司的實繳出資事項符合公司的發展方向,有利於推動公司裝備製造和城市運維管理的產業佈局,提升公司整體實力,逐步實施公司戰略規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.